Group 1 - The core point of the article is that Yongtai Biological-B (06978.HK) announced an investment in a structured deposit product with SPD Bank, amounting to RMB 50 million [1] Group 2 - The investment is scheduled for February 25, 2026, indicating a future commitment by the company [1] - The structured deposit product represents a strategic financial move for the company, potentially aimed at optimizing cash management [1]

另一位"团员"宝马集团董事长齐普策在随德国总理默茨访华期间表示："当今世界，全球性挑战纷繁交 织，合作是应对变局、开创未来的必由之路。德国总理此次访华，向世界传递了持续对话、深化合作的 鲜明信号，同时也为宝马同中国伙伴未来继续挖掘合作潜力奠定了基础。国际环境越复杂，越需要各国 敞开胸怀，摒弃误解偏见，加强沟通对话，增进政治互信，维护世界和平与稳定。" 《中国经营报》记者采访了解到，作为德国先进的汽车制造商以及最早进入中国市场的跨国企业，大众 汽车集团（中国）方面就德国总理默茨访华表示："在全球格局日渐动荡分化的背景下，德国总理弗里 德里希·默茨此次访华，释放出稳定、对话与务实合作的重要信号。作为欧洲最大经济体，德国在塑造 欧中经贸关系方面发挥着关键作用。对大众汽车集团、德国乃至整个欧洲的工业界而言，中国的意义不 仅仅是销售市场，更是创新的策源地和技术合作伙伴，同时也是全球价值创造体系中的一大支柱。在电 动出行、软件、人工智能和电池技术等领域，中国正以全球领先的速度引领发展节奏，并塑造行业标 准。无论是在出行还是可再生能源等关键领域，任何真正致力于推动转型的企业，都不可能忽视中 国。" 刚刚迎来品牌140周年的 ...

Group 1 - The core inquiry from investors is whether China Resources Group possesses blood station resources and if it will inject these into Boya Bio [2] - Boya Bio (300294.SZ) confirmed on the investor interaction platform that it is part of the China Resources Health sector's blood products platform [2] - As of now, Boya Bio holds a total of 2 blood product production licenses and operates 21 single plasma collection stations, including 4 under the Green Cross brand [2]

Group 1 - The core issue raised by investors concerns the adjustment of the value-added tax (VAT) rate from 3% to 13% and its potential impact on the company's tax costs and profits [1] - The company clarified that rare disease drugs within blood products, such as PCC and factors VIII and IX, will continue to be subject to the 3% simplified tax rate, while other blood product businesses will no longer qualify for this rate [1] - The company emphasized its commitment to improving supply chain management and operational practices in response to tax policy changes, aiming to create value for the company and its shareholders [1]

Summary of Marker Therapeutics FY Conference Call Company Overview - **Company**: Marker Therapeutics (NasdaqCM:MRKR) - **Focus**: Immuno-oncology, specifically T-cell therapies using the MAR-T platform - **Lead Program**: MT-601, targeting relapse lymphoma and expanding into solid tumors [1][2] Core Technology and Differentiation - **Technology**: MAR-T cells, a first-in-class technology that does not require genetic modification and can target multiple antigens [2][3] - **Safety Profile**: Excellent safety with no observed ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) or HLH (Hemophagocytic Lymphohistiocytosis), and low-level CRS (Cytokine Release Syndrome) limited to fever [4][13] - **Manufacturing Process**: Simplified and efficient, with a current vein-to-vein time of 22 days, expected to reduce to 17 days [5][7] Clinical Data and Efficacy - **Response Rates**: - Non-Hodgkin lymphoma: Overall response rate of 66%, complete response rate of 50% [10] - Hodgkin lymphoma: Overall response rate of 78% [12] - **Patient Demographics**: Patients heavily pretreated and refractory to multiple lines of treatment, including CAR T cells [10][12] - **Durability of Responses**: Some patients have surpassed one year of follow-up, with sustained responses noted [10][11] Financial and Market Position - **Funding**: Received over $30 million from government sources, providing a non-dilutive capital runway [4][17] - **Market Opportunity**: Potential market for LBCL (Large B-cell Lymphoma) after CAR T-cell treatment could exceed $3 billion by 2030 [14] Future Plans and Milestones - **Clinical Trials**: Advancing MT-601 into a pivotal single-arm phase 2b study for lymphoma, with plans to enroll patients in pancreatic cancer [8][15] - **Upcoming Milestones**: Completion of tech transfer to a new CDMO (Contract Development and Manufacturing Organization) and additional patient readouts expected [17] Industry Sentiment and Challenges - **Market Sentiment**: General cold sentiment towards cell therapy and CAR T cells due to complexities and limitations [19][20] - **Strategic Positioning**: Marker Therapeutics aims to differentiate itself by addressing the limitations of existing CAR T technologies, focusing on a simpler manufacturing process and broader applicability beyond CD19-targeted therapies [20][21] Conclusion - Marker Therapeutics is positioned to leverage its unique MAR-T technology to address significant unmet medical needs in oncology, with promising clinical data and a clear path towards market entry. The company is focused on advancing its lead asset, MT-601, while exploring opportunities in solid tumors and off-the-shelf therapies.

Core Viewpoint - Jiuyuan Gene (02566) has announced that the listing application for its product, Jikeqin, has been accepted by the National Medical Products Administration of China, marking a significant step in the development of its long-acting GLP-1 receptor agonist, semaglutide biosimilar [1] Group 1: Product Development - Jikeqin is developed as a biosimilar of semaglutide, classified under biological drug registration category 3.3, intended for weight management in obese or overweight populations [1] - The product mimics the physiological effects of endogenous GLP-1 hormone, promoting insulin secretion, inhibiting glucagon release, suppressing appetite, and delaying gastric emptying to improve blood sugar control and facilitate weight management [1] Group 2: Clinical Trials - Phase III clinical trials have been conducted with Jikeqin in obese subjects, featuring a randomized, open-label, positive control, parallel design to assess clinical equivalence [1] - Results from the trials indicate that Jikeqin demonstrates clinical equivalence to the reference drug in terms of primary efficacy indicators (weight change rate after 44 weeks of treatment) and safety, showcasing good efficacy and tolerability [1] Group 3: Regulatory Milestones - The company received the drug clinical trial approval notice from the National Medical Products Administration in January 2024 and completed the enrollment of all subjects for the Phase III clinical study by December 2024 [1] - The application for market listing has been submitted to the National Drug Review Center for evaluation [1]

Core Viewpoint - Jiuyuan Gene (02566) has received acceptance for the listing application of its product, Jikeqin®, by the National Medical Products Administration of China, marking a significant step in the development of its long-acting GLP-1 receptor agonist, semaglutide biosimilar [1] Group 1: Product Development - Jikeqin® is developed as a biosimilar of semaglutide, classified under biological drug registration category 3.3, intended for weight management in obese or overweight populations [1] - The product mimics the physiological effects of endogenous GLP-1 hormone, promoting insulin secretion, inhibiting glucagon release, suppressing appetite, and delaying gastric emptying to improve blood sugar control and facilitate weight management [1] Group 2: Clinical Trials - A Phase III clinical trial has been conducted, featuring a randomized, open-label, positive-controlled, parallel design to assess the clinical equivalence of Jikeqin® in obese subjects [1] - Results from the trial indicate that Jikeqin® demonstrates clinical equivalence to the reference drug in terms of primary efficacy indicators (weight change rate after 44 weeks of treatment) and safety, showcasing good efficacy and tolerability [1] Group 3: Regulatory Milestones - Jikeqin® received the drug clinical trial approval notice from the National Medical Products Administration in January 2024 and completed the enrollment of all subjects for the Phase III clinical study by December 2024 [1] - The application materials for the listing have been submitted to the National Drug Review Center for evaluation [1]

Core Viewpoint - Jiuyuan Gene (02566.HK) has announced that the application for the market launch of its product, Jikeqin®, has been accepted by the National Medical Products Administration of the People's Republic of China [1] Group 1: Product Development - Jikeqin® is a long-acting GLP-1 receptor agonist, a biosimilar to semaglutide, aimed at weight management for obese or overweight individuals [1] - The product is classified under Category 3.3 for biological drug registration and mimics the physiological effects of endogenous GLP-1 hormone [1] Group 2: Mechanism of Action - Jikeqin® promotes insulin secretion, inhibits glucagon release, suppresses appetite, and delays gastric emptying, thereby improving blood glucose control and facilitating weight management [1] Group 3: Clinical Trials - Phase III clinical trials have shown that Jikeqin® demonstrates clinical equivalence in primary efficacy indicators and safety compared to the reference drug [1] - The trials involved a randomized, open-label, positive-controlled, parallel design and were conducted on obese subjects [1] Group 4: Regulatory Milestones - The drug received a clinical trial approval notice from the National Medical Products Administration in January 2024 and completed the enrollment of all Phase III clinical trial subjects by December 2024 [1] - The application for market launch has been submitted to the National Drug Review Center for evaluation [1]

Group 1 - The core focus of multinational pharmaceutical collaborations is strategic alignment, specifically whether the disease area of the collaborative asset can effectively complement the existing pipeline [2] - The differentiation advantages and research progress of the asset itself are crucial, with solid research data, significant differentiation features, and industry-leading research advancement pace being key considerations [2] - GSK possesses a highly specialized research team with advanced advantages in relevant fields, which is highly valued by the company, reflecting GSK's capabilities in biomedical research, global clinical development, commercialization layout, and global resource integration [2]

Core Viewpoint - The company, 3SBio Inc. (三生国健), has received acceptance for its new drug application (NDA) for SSGJ-611, a humanized monoclonal antibody targeting IL-4Rα, from the National Medical Products Administration (NMPA) [1] Group 1 - The product SSGJ-611 is a self-developed and designed humanized monoclonal antibody with a novel amino acid sequence [1] - SSGJ-611 works by specifically binding to IL-4Rα, blocking the signaling of IL-4 and IL-13, which helps alleviate conditions such as atopic dermatitis [1]